Building An Oncology Business In China: Balancing Access And Pricing Freedom
The question facing many pharmaceutical companies is whether to pursue drug coverage through China's rapidly evolving health care reimbursement system or tap the fast expanding self-pay market. There's no one-size fits all answer, but understanding the nuances of the local market is essential to getting the strategy right.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.